Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.

Affiliation

Wu Z(1), Hu Y(2), Xu M(3), Chen Z(3), Yang W(2), Jiang Z(4), Li M(1), Jin H(5), Cui G(6), Chen P(5), Wang L(2), Zhao G(4), Ding Y(5), Zhao Y(7), Yin W(8).
Author information:
(1)Hebei Provincial Center for Disease Control and Prevention, Shijiazhuang, Hebei, China.
(2)Sinovac Biotech, Beijing, China.
(3)National Institutes for Food and Drug Control, Beijing, China.
(4)Beijing Key Tech Statistics Technology, Beijing, China.
(5)Renqiu City Center for Disease Control and Prevention, Renqiu, Hebei, China.
(6)Sinovac Life Sciences, Beijing, China.
(7)Hebei Provincial Center for Disease Control and Prevention, Shijiazhuang, Hebei, China. Electronic address: [Email]
(8)Sinovac Biotech, Beijing, China. Electronic address: [Email]

Abstract

Comment in Lancet Infect Dis. 2021 Jun;21(6):746-748.